VivoSeq
Other

Immune Tolerance

0

Pipeline Programs↗

3

Active Trials↗

4

Companies Involved↗

Immune Tolerance is an early-stage landscape with 0 programs across 4 companies. The most active players are Sanofi, Novartis, Novo Nordisk.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

64/100

Attrition Rate

27/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalNovo Nordisk logo

Novo Nordisk

0 programs

PreclinicalOctapharma logo

Octapharma

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

15

clinical trials

Completed7 · 47%
Terminated4 · 27%
Recruiting3 · 20%
Unknown status1 · 7%

Clinical Trials

Trial Activity

15 trials

TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Termination
Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT06478537·56 enrolled
Phase I Study of Combined Deceased Donor Kidney and Hematopoietic Cell Transplants Using a Regimen to Promote Hematopoietic Cell Engraftment
Recruiting·SStanford University·Phase 1·NCT04571203·30 enrolled
Total Lymphoid Irradiation, Anti-Thymocyte Globulin and Purified Donor CD34+ and T-cell Transfusion to Withdraw Immunosuppressive Drugs From Recipients of a Previous HLA Matched Living Donor Kidney Transplantation .
Recruiting·—·Phase 1·NCT03591302·25 enrolled
A Study to Determine the Capacity of VAK694 When Combined With Allergen Immunotherapy to Bring About Specific Immune Tolerance
Completed·Novartis logoNovartis·Phase 2·NCT01018693·37 enrolled
Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout
Completed·UUniversity of California, Los Angeles·Phase 1·NCT06186219·2 enrolled
Diabetes Prevention - Immune Tolerance
Completed·LLund University·Phase 2·NCT01122446·50 enrolled
Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies
Completed·SSwedish Orphan Biovitrum·Phase 4·NCT03103542·16 enrolled
Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced)
Completed·—·N/A·NCT01051076·3 enrolled
AZD1656 in Transplantation With Diabetes tO PromoTe Immune TOleraNce
Completed·QQueen Mary University of London·Phase 2·NCT05216172·26 enrolled
Immune Tolerance Study With Aldurazyme® (Laronidase)
Completed·Sanofi logoSanofi·Phase 1/2·NCT00741338·7 enrolled
International Immune Tolerance Study
Terminated·NNew York Presbyterian Hospital·N/A·NCT00212472·134 enrolled
Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial
Terminated·Novo Nordisk logoNovo Nordisk·Phase 3·NCT03588741·1 enrolled
Immune Tolerance Induction Study
Terminated·Sanofi logoSanofi·Phase 4·NCT00701701·4 enrolled
Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq
Terminated·Octapharma logoOctapharma·N/A·NCT03344003·14 enrolled
Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients
Unknown status·FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico·Phase 4·NCT02479087·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)